Key Points
- Director Michael Hoffman purchased 45,000 shares of Annovis Bio at an average price of $4.31 on Dec. 8 for ~$193,950, increasing his stake to 2,574,739 shares (a 1.78% rise) per an SEC filing.
- Annovis Bio (ANVS) trades around $4.33 with a market cap of about $114.8M
- Institutional investors have been active—Vanguard increased its position to 738,003 shares (adding 41,239), and other firms like Jane Street, Marshall Wace, and JPMorgan have recently established or grown positions; institutions own about 15.83% of the stock.
Annovis Bio, Inc. (NYSE:ANVS - Get Free Report) Director Michael Hoffman acquired 45,000 shares of the stock in a transaction dated Monday, December 8th. The shares were purchased at an average cost of $4.31 per share, with a total value of $193,950.00. Following the completion of the purchase, the director owned 2,574,739 shares of the company's stock, valued at approximately $11,097,125.09. The trade was a 1.78% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Annovis Bio Price Performance
NYSE ANVS opened at $4.33 on Tuesday. Annovis Bio, Inc. has a 1 year low of $1.11 and a 1 year high of $6.37. The stock has a market capitalization of $114.80 million, a PE ratio of -3.01 and a beta of 1.48. The business's 50-day moving average is $2.78 and its 200 day moving average is $2.62.
Annovis Bio (NYSE:ANVS - Get Free Report) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.01). As a group, equities research analysts anticipate that Annovis Bio, Inc. will post -2.19 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of analysts recently commented on the company. HC Wainwright dropped their price target on Annovis Bio from $12.00 to $10.00 and set a "buy" rating for the company in a research note on Wednesday, September 3rd. Canaccord Genuity Group reaffirmed a "buy" rating and set a $17.00 target price on shares of Annovis Bio in a research note on Tuesday, September 30th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Annovis Bio in a research note on Monday, December 1st. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $13.50.
Read Our Latest Stock Analysis on ANVS
Institutional Trading of Annovis Bio
Hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. increased its stake in shares of Annovis Bio by 5.9% in the 3rd quarter. Vanguard Group Inc. now owns 738,003 shares of the company's stock worth $1,528,000 after acquiring an additional 41,239 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Annovis Bio during the second quarter valued at approximately $52,000. Marshall Wace LLP bought a new position in shares of Annovis Bio during the second quarter valued at approximately $197,000. JPMorgan Chase & Co. lifted its holdings in shares of Annovis Bio by 69.3% during the second quarter. JPMorgan Chase & Co. now owns 14,900 shares of the company's stock valued at $32,000 after purchasing an additional 6,100 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Annovis Bio by 20.1% in the 2nd quarter. Geode Capital Management LLC now owns 183,287 shares of the company's stock worth $398,000 after purchasing an additional 30,674 shares in the last quarter. 15.83% of the stock is owned by hedge funds and other institutional investors.
Annovis Bio Company Profile
(
Get Free Report)
Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
